NASDAQ: RAPPRapport Therapeutics Inc Stock Ownership - Who owns Rapport Therapeutics?
Insider buying vs selling
Have Rapport Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| David Bredt | Chief Scientific Officer | 2025-04-15 | 8,500 | $9.57 | $81.31kSell |
| David Bredt | Chief Scientific Officer | 2025-03-14 | 8,500 | $10.85 | $92.21kSell |
| Troy A. Ignelzi | Chief Financial Officer | 2025-03-13 | 100 | $9.98 | $998.00Buy |
| Wendy B. Young | Director | 2025-03-12 | 6,000 | $10.21 | $61.25kBuy |
| Troy A. Ignelzi | Chief Financial Officer | 2025-03-12 | 9,900 | $10.10 | $99.99kBuy |
| James Healy | Director | 2024-07-01 | 3,565 | $24.21 | $86.32kBuy |
| James Healy | Director | 2024-07-01 | 3,538 | $23.08 | $81.64kBuy |
| James Healy | Director | 2024-07-01 | 2,625 | $26.06 | $68.39kBuy |
| James Healy | Director | 2024-07-01 | 4,661 | $25.02 | $116.60kBuy |
| James Healy | Director | 2024-07-01 | 3,657 | $24.21 | $88.54kBuy |
RAPP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when RAPP insiders and whales buy or sell their stock.
RAPP Shareholders
What type of owners hold Rapport Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Third Rock Ventures V LP | 22.21% | 8,104,451 | $92.23M | Insider |
| Trv GP V LLC | 19.55% | 7,135,233 | $81.20M | Institution |
| Fmr LLC | 15.03% | 5,486,468 | $62.44M | Institution |
| Arch Venture Partners XII LLC | 10.22% | 3,728,738 | $42.43M | Insider |
| Arch Venture Management LLC | 10.22% | 3,728,738 | $42.43M | Institution |
| Cormorant Asset Management LP | 8.06% | 2,940,921 | $33.47M | Institution |
| Capital International Investors | 7.13% | 2,602,529 | $29.62M | Institution |
| Johnson Johnson | 6.84% | 2,498,051 | $28.43M | Institution |
| James Healy | 5.47% | 1,995,594 | $22.71M | Insider |
| Sofinnova Investments Inc | 5.47% | 1,995,594 | $22.71M | Institution |
RAPP vs Biotech Stocks
Rapport Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.